290 related articles for article (PubMed ID: 20171418)
21. Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.
Berman S; Rannie M; Moore L; Elias E; Dryer LJ; Jones MD
Pediatrics; 2005 Jun; 115(6):e637-42. PubMed ID: 15930189
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry.
Uchiyama S; Goto S; Matsumoto M; Nagai R; Origasa H; Yamazaki T; Shigematsu H; Shimada K; Yamada N; Bhatt DL; Steg PG; Ikeda Y;
J Neurol Sci; 2009 Dec; 287(1-2):45-51. PubMed ID: 19815240
[TBL] [Abstract][Full Text] [Related]
23. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
[TBL] [Abstract][Full Text] [Related]
24. National health care costs of peripheral arterial disease in the Medicare population.
Hirsch AT; Hartman L; Town RJ; Virnig BA
Vasc Med; 2008 Aug; 13(3):209-15. PubMed ID: 18687757
[TBL] [Abstract][Full Text] [Related]
25. Economic implications of obesity among people with atherothrombotic disease.
Ademi Z; Walls HL; Peeters A; Liew D; Hollingsworth B; Stevenson C; Steg PG; Bhatt DL; Reid CM
Int J Obes (Lond); 2010 Aug; 34(8):1284-92. PubMed ID: 20195286
[TBL] [Abstract][Full Text] [Related]
26. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
27. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry.
Smolderen KG; Bell A; Lei Y; Cohen EA; Steg PG; Bhatt DL; Mahoney EM;
Can J Cardiol; 2010 Oct; 26(8):297-305. PubMed ID: 20931098
[TBL] [Abstract][Full Text] [Related]
28. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
29. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
Mark DB; Knight JD; Cowper PA; Davidson-Ray L; Anstrom KJ
Am Heart J; 2008 Oct; 156(4):698-705. PubMed ID: 18926150
[TBL] [Abstract][Full Text] [Related]
30. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients.
Delong LK; Culler SD; Saini SS; Beck LA; Chen SC
Arch Dermatol; 2008 Jan; 144(1):35-9. PubMed ID: 18209166
[TBL] [Abstract][Full Text] [Related]
31. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of drugs in peripheral vascular disease and stroke.
Drummond M; Davies L
J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S4-7. PubMed ID: 7517476
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing the cost of hospital care for people with diabetes in Australia.
Clarke P; Kelman C; Colagiuri S
J Diabetes Complications; 2006; 20(6):349-55. PubMed ID: 17070437
[TBL] [Abstract][Full Text] [Related]
34. Self-reported health risks linked to health plan cost and age group.
Hill RK; Thompson JW; Shaw JL; Pinidiya SD; Card-Higginson P
Am J Prev Med; 2009 Jun; 36(6):468-74. PubMed ID: 19460654
[TBL] [Abstract][Full Text] [Related]
35. The cost of obesity in Canada.
Birmingham CL; Muller JL; Palepu A; Spinelli JJ; Anis AH
CMAJ; 1999 Feb; 160(4):483-8. PubMed ID: 10081464
[TBL] [Abstract][Full Text] [Related]
36. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
37. Outcomes and excess costs among patients with cardiovascular disease.
Ademi Z; Liew D; Zomer E; Gorelik A; Hollingsworth B; Steg PG; Bhatt DL; Reid CM
Heart Lung Circ; 2013 Sep; 22(9):724-30. PubMed ID: 23510668
[TBL] [Abstract][Full Text] [Related]
38. Temporal trends in the incidence and recurrence of hospitalised atherothrombotic disease in an Australian population, 2000-07: data linkage study.
Nedkoff L; Briffa TG; Knuiman M; Hung J; Norman PE; Hankey GJ; Thompson PL; Geelhoed E; Sanfilippo FM; Hickling S; Bremner A; Hobbs M
Heart; 2012 Oct; 98(19):1449-56. PubMed ID: 22821274
[TBL] [Abstract][Full Text] [Related]
39. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study.
Shih YC; Xu Y; Cormier JN; Giordano S; Ridner SH; Buchholz TA; Perkins GH; Elting LS
J Clin Oncol; 2009 Apr; 27(12):2007-14. PubMed ID: 19289624
[TBL] [Abstract][Full Text] [Related]
40. Cost of dental services provided in private general practice for an insured population in New South Wales, Australia.
Sivaneswaran S; Taylor R; Lazarus R
Community Dent Health; 2000 Dec; 17(4):246-53. PubMed ID: 11191200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
